EGFR-mutated lung cancers resistant to osimertinib through EGFR-C797S respond to 1(st) generation reversible EGFR inhibitors but eventually acquire EGFR-T790M/C797S in preclinical models and clinical samples

INTRODUCTION: Osimertinib is approved for advanced epidermal growth factor receptor (EGFR)- mutated non-small-cell lung cancer (NSCLC), and identification of on-target mechanisms of resistance (i.e. EGFR-C797S) to this 3(rd) generation EGFR inhibitor are evolving. Whether durable control of subseque...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Oncol
Main Authors: Rangachari, Deepa, To, Ciric, Shpilsky, Jason E., VanderLaan, Paul A., Kobayashi, Susumu S., Mushajiang, Mierzhati, Lau, Christie J., Paweletz, Cloud P., Oxnard, Geoffrey R., Jänne, Pasi A., Costa, Daniel B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6823139/
https://ncbi.nlm.nih.gov/pubmed/31377341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2019.07.016
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados